Full-Time

Regional Business Director

Migraine

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Compensation Overview

$170k - $205kAnnually

+ Bonus + Equity

Senior

Dallas, TX, USA

Must live within the territory’s geography.

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • BA or BS required. Advanced degree preferred
  • 5 years or more of field leadership experience and/or payer account management and/or demonstrated sales success with increasing responsibility and organizational leadership
  • Previous pharmaceutical, biotech, or medical marketing/sales experience preferred with at least three to five years spent in a position with demonstrated 1st line leadership groups
  • Proven performance history in the ability to lead others to success through your coaching influence
  • Demonstrated experience delivering outstanding results and developing others to their potential
  • Proven track record in attracting and retaining top talent
  • Current or recent Migraine disease experience strongly preferred
  • Successful launch experience strongly preferred
  • Experience to strategize within teams using differential resources to reach business goals
  • Proven ability to run multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Must live within the territory’s geography
  • Comfortable with uncertainty and high expectations
  • Patient support services experience a plus
  • Strong digital marketing aptitude
  • Strong interpersonal and presentation skills
Responsibilities
  • Responsible for supervising operations of the Region which includes: driving results, hiring and coaching, account manager development, performance management, and the assignment of key "priority" accounts within the medical community
  • Develop and implement strategic plans for the Region including the right balance of live/virtual interactions and the prioritization of efforts by the team
  • Plan, organize and drive performance to achieve the business potential of the region through coaching and influence of direct reports
  • Establish and maintain effective communication among all members of the Region across cross-channel stakeholders in the Accounts and Market Access team
  • Maintain required technical expertise in order to respond accurately to all questions regarding products, marketing, policies, and business-related issues from customers and account managers
  • Work with direct reports to understand and consistently execute established expectations
  • Consistently exemplify the ability to help a SAM improve on their selling skills, account management, product knowledge and capabilities needed for success through coaching and counsel. Lead by example through coaching direct reports both in live and virtual engagements
  • Effectively plan and conduct plan of action and other meetings with members of the Region and Market Access teams
  • Develop and implement Region business plan, manage Region budget and overall responsibility for P&L at Region level in alignment with Regional and National expectations
  • Have a complete understanding of all relevant compliance laws, policies and processes and ensure actions of self and team are fully compliant
  • Overnight travel as indicated by the needs of the business
  • Additional responsibilities as assigned
Desired Qualifications
  • Previous pharmaceutical, biotech, or medical marketing/sales experience preferred with at least three to five years spent in a position with demonstrated 1st line leadership groups
  • Current or recent Migraine disease experience strongly preferred
  • Successful launch experience strongly preferred
  • Patient support services experience a plus
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which speeds up its development process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased investment in CNS treatments boosts Axsome's pipeline potential.
  • FDA's fast-tracking emphasis could expedite Axsome's drug approvals, especially AXS-05.
  • Personalized medicine trends offer Axsome opportunities for tailored, effective therapies.

What critics are saying

  • Increased competition in CNS treatments may impact Axsome's market share.
  • Potential delays in AXS-07 approval could affect launch timeline and revenue.
  • Reliance on key products like AXS-05 makes Axsome vulnerable to setbacks.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders, addressing unmet medical needs with innovative therapies.
  • AXS-05, a flagship product, has FDA Breakthrough Therapy Designation for depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Insider Monkey
Feb 23rd, 2025
Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).